Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Average Recommendation of “Moderate Buy” by Analysts

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been given a consensus rating of “Moderate Buy” by the fourteen research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating and thirteen have given a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $45.80.

Several brokerages have issued reports on AVTX. BTIG Research reiterated a “buy” rating and set a $58.00 target price on shares of Avalo Therapeutics in a research report on Tuesday, June 16th. Wedbush decreased their price target on shares of Avalo Therapeutics from $40.00 to $34.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Leerink Partners initiated coverage on shares of Avalo Therapeutics in a research report on Monday, July 6th. They set an “outperform” rating and a $38.00 price objective on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $60.00 price objective (up from $48.00) on shares of Avalo Therapeutics in a report on Monday, May 11th. Finally, Citigroup reiterated an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th.

Avalo Therapeutics Price Performance

Avalo Therapeutics stock opened at $19.21 on Monday. Avalo Therapeutics has a one year low of $4.61 and a one year high of $24.27. The business has a fifty day moving average price of $16.90 and a 200-day moving average price of $16.09. The firm has a market capitalization of $1.01 billion, a P/E ratio of -3.52 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.02. Sell-side analysts expect that Avalo Therapeutics will post -2.58 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Paul Varki sold 75,063 shares of the company’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the completion of the transaction, the insider directly owned 3,634 shares of the company’s stock, valued at approximately $73,297.78. This represents a 95.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 1,450 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the transaction, the insider directly owned 51,776 shares in the company, valued at $931,968. This trade represents a 2.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 93,428 shares of company stock worth $1,762,722 in the last 90 days. 4.46% of the stock is owned by company insiders.

Institutional Investors Weigh In On Avalo Therapeutics

Several hedge funds have recently bought and sold shares of the business. PFS Partners LLC increased its position in Avalo Therapeutics by 100.0% during the 4th quarter. PFS Partners LLC now owns 2,000 shares of the company’s stock valued at $36,000 after buying an additional 1,000 shares in the last quarter. Boothbay Fund Management LLC purchased a new position in Avalo Therapeutics during the second quarter valued at $56,000. Dimensional Fund Advisors LP bought a new stake in Avalo Therapeutics in the third quarter worth $143,000. AlphaCentric Advisors LLC bought a new stake in Avalo Therapeutics in the first quarter worth $174,000. Finally, Jump Financial LLC purchased a new stake in shares of Avalo Therapeutics in the fourth quarter worth $238,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.